Cargando…
Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report
Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion (PE) in patients with advanced non-small cell lung cancer (NSCLC) remain...
Autores principales: | , , , , , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399467/ https://www.ncbi.nlm.nih.gov/pubmed/37529904 http://dx.doi.org/10.1080/21645515.2023.2240689 |
_version_ | 1785084252168126464 |
---|---|
author | Xie, Xiao-Hong Shen, Pan-Xiao Wu, Jian-Hui Qiu, Gui-Huan Lin, Xin-Qing Xie, Zhan-Hong Qin, Yin-Yin Zheng, Bin Liu, Ming Zhou, Cheng-Zhi |
author_facet | Xie, Xiao-Hong Shen, Pan-Xiao Wu, Jian-Hui Qiu, Gui-Huan Lin, Xin-Qing Xie, Zhan-Hong Qin, Yin-Yin Zheng, Bin Liu, Ming Zhou, Cheng-Zhi |
author_sort | Xie, Xiao-Hong |
collection | PubMed |
description | Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion (PE) in patients with advanced non-small cell lung cancer (NSCLC) remains unclear. In this report, we present the case of an advanced NSCLC patient who developed persistent PE despite receiving camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) and chemotherapy as first-line treatment. While the patient’s tumor biomarkers decreased after multiple cycles of treatment, the PE persisted despite negative findings on cytology and pleural biopsy. Additionally, the use of anti-angiogenic drugs failed to alleviate the PE. Screening for rheumatic connective tissue markers and tuberculosis yielded negative results, but intrathoracic dexamethasone injections in two doses resulted in a significant reduction of the PE. This case suggests that PE may represent a rare type of irAE that should be monitored for during prolonged immuno-oncology therapy. |
format | Online Article Text |
id | pubmed-10399467 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2023 |
publisher | Taylor & Francis |
record_format | MEDLINE/PubMed |
spelling | pubmed-103994672023-08-04 Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report Xie, Xiao-Hong Shen, Pan-Xiao Wu, Jian-Hui Qiu, Gui-Huan Lin, Xin-Qing Xie, Zhan-Hong Qin, Yin-Yin Zheng, Bin Liu, Ming Zhou, Cheng-Zhi Hum Vaccin Immunother Immunotherapy - Cancer Immune-related adverse events (irAEs) pose a significant challenge for the widespread adoption of immuno-oncology therapies, but their symptoms can vary widely. In particular, the relationship between irAEs and pleural effusion (PE) in patients with advanced non-small cell lung cancer (NSCLC) remains unclear. In this report, we present the case of an advanced NSCLC patient who developed persistent PE despite receiving camrelizumab (an anti-programmed death receptor 1 [PD-1] antibody) and chemotherapy as first-line treatment. While the patient’s tumor biomarkers decreased after multiple cycles of treatment, the PE persisted despite negative findings on cytology and pleural biopsy. Additionally, the use of anti-angiogenic drugs failed to alleviate the PE. Screening for rheumatic connective tissue markers and tuberculosis yielded negative results, but intrathoracic dexamethasone injections in two doses resulted in a significant reduction of the PE. This case suggests that PE may represent a rare type of irAE that should be monitored for during prolonged immuno-oncology therapy. Taylor & Francis 2023-08-02 /pmc/articles/PMC10399467/ /pubmed/37529904 http://dx.doi.org/10.1080/21645515.2023.2240689 Text en © 2023 The Author(s). Published with license by Taylor & Francis Group, LLC. https://creativecommons.org/licenses/by-nc/4.0/This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial License (http://creativecommons.org/licenses/by-nc/4.0/ (https://creativecommons.org/licenses/by-nc/4.0/) ), which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited. The terms on which this article has been published allow the posting of the Accepted Manuscript in a repository by the author(s) or with their consent. |
spellingShingle | Immunotherapy - Cancer Xie, Xiao-Hong Shen, Pan-Xiao Wu, Jian-Hui Qiu, Gui-Huan Lin, Xin-Qing Xie, Zhan-Hong Qin, Yin-Yin Zheng, Bin Liu, Ming Zhou, Cheng-Zhi Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title | Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title_full | Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title_fullStr | Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title_full_unstemmed | Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title_short | Recurrent pleural effusion as a rare manifestation after prolonged PD1 inhibitor (camrelizumab)-based immunotherapy: A case report |
title_sort | recurrent pleural effusion as a rare manifestation after prolonged pd1 inhibitor (camrelizumab)-based immunotherapy: a case report |
topic | Immunotherapy - Cancer |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10399467/ https://www.ncbi.nlm.nih.gov/pubmed/37529904 http://dx.doi.org/10.1080/21645515.2023.2240689 |
work_keys_str_mv | AT xiexiaohong recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT shenpanxiao recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT wujianhui recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT qiuguihuan recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT linxinqing recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT xiezhanhong recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT qinyinyin recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT zhengbin recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT liuming recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport AT zhouchengzhi recurrentpleuraleffusionasararemanifestationafterprolongedpd1inhibitorcamrelizumabbasedimmunotherapyacasereport |